<DOC>
	<DOC>NCT00403403</DOC>
	<brief_summary>This is a placebo-controlled, double-blind, multicenter, randomized study for preliminary evaluation of the efficacy and safety of combining bevacizumab with cisplatin (or carboplatin) and etoposide in patients with previously untreated extensive-stage small cell lung cancer (SCLC).</brief_summary>
	<brief_title>A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histologically or cytologically documented small cell carcinoma of the bronchus, classified as extensivestage disease Measurable disease or lesions Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 Life expectancy of &lt; 12 weeks Current, recent, or planned participation in another experimental drug study Ongoing or active infection Active malignancy other than SCLC or superficial basal/squamous cell carcinoma within the previous 5 years Prior systemic therapy, radiation therapy, or surgery for SCLC Inadequate bone marrow function, renal function, or hepatic function Serum sodium of &lt; 120 mg/dL Inadequately controlled hypertension History of hypertensive crisis or hypertensive encephalopathy New York Heart Association Class II or greater congestive heart failure History of myocardial infarction or unstable angina within 6 months prior to study enrollment History of stroke or transient ischemic attack within 6 months prior to study enrollment Known central nervous system disease, except for brain metastases treated with wholebrain radiotherapy Significant vascular disease or recent peripheral arterial thrombosis within 6 months prior to study enrollment History of hemoptysis within 4 weeks prior to study enrollment Evidence of bleeding diathesis or coagulopathy in the absence of therapeutic anticoagulation Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of a need for a major surgical procedure during the course of the study Core biopsy or other minor surgical procedure, including placement of a vascular access device, within 7 days prior to Day 1 History of abdominal fistula or gastrointestinal perforation within 6 months prior to study enrollment Serious, nonhealing wound, active ulcer, or untreated bone fracture Known hypersensitivity to any component of bevacizumab Pregnant (positive pregnancy test) or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>SCLC</keyword>
	<keyword>SALUTE</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Avastin</keyword>
</DOC>